Huminsulin R 100IU/ml Solution for Injection contains human insulin at a concentration of 100 international units per milliliter, intended for the management of diabetes mellitus requiring insulin therapy. This short-acting insulin formulation mimics endogenous insulin, facilitating glucose uptake in peripheral tissues and inhibiting hepatic glucose production, thereby aiding in the control of blood glucose levels. Huminsulin R is typically administered subcutaneously, with dosing individualized based on patient-specific factors such as blood glucose monitoring results, dietary intake, and physical activity. It may also be used intravenously in emergency situations such as diabetic ketoacidosis under medical supervision. Onset of action occurs within 30 minutes, with peak effects observed between 2 to 4 hours and a duration of action lasting approximately 6 to 8 hours. Patients should rotate injection sites to reduce the risk of lipodystrophy. Caution is advised to avoid hypoglycemia, which may result from excessive insulin dosing, missed meals, or increased physical activity. Huminsulin R should be stored under recommended conditions to maintain potency. This product is contraindicated in patients with hypoglycemia or hypersensitivity to human insulin or any excipients. Regular monitoring of blood glucose and adjustment of dosage are essential to optimize therapeutic outcomes.